(Q33270841)

24 July 2017

0 references

1 reference

title

A systematic review on clinical management of antipsychotic-induced sexual dysfunction in schizophrenia (English)

1 reference

24 July 2017

0 references

1 reference

1 reference

Anna Maria Niccolai Costa

series ordinal

1

1 reference

24 July 2017

Mauricio Silva de Lima

series ordinal

2

1 reference

24 July 2017

Jair de Jesus Mari

series ordinal

3

1 reference

24 July 2017

publication date

1 September 2006

1 reference

Sao Paulo Medical Journal

24 July 2017

published in

1 reference

24 July 2017

volume

124

1 reference

24 July 2017

issue

5

1 reference

24 July 2017

page(s)

291-297

1 reference

Zuclopenthixol acetate in the treatment of acute schizophrenia and similar serious mental illnesses

24 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1590%2FS1516-31802006000500012

Risperidone versus other atypical antipsychotic medication for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-31802006000500012

Quetiapine for schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-31802006000500012

Different patterns of sexual dysfunctions associated with psychiatric disorders and psychopharmacological treatment. Results of an investigation by semistructured interview of schizophrenic and neurotic patients and methadone-substituted opiate addi

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-31802006000500012

21 January 2018

Neuroleptic intolerance

1 reference

https://api.crossref.org/works/10.1590%2FS1516-31802006000500012

Use of the dopamine agonists bromocriptine and cabergoline in the management of risperidone-induced hyperprolactinemia in patients with psychotic disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-31802006000500012

Low-dose imipramine for thioridazine-induced male orgasmic disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-31802006000500012

Sildenafil and erectile dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-31802006000500012

Sildenafil use in patients with olanzapine-induced erectile dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-31802006000500012

Possible mechanisms of action of (-)deprenyl and other MAO-B inhibitors in some neurologic and psychiatric disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-31802006000500012

Selegiline in the treatment of sexual dysfunction in schizophrenic patients maintained on neuroleptics: a pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-31802006000500012

Brom-ergocryptine in the Treatment of Phenothiazine-Induced Galactorrhoea

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-31802006000500012

Treatment of risperidone-induced hyperprolactinemia with a dopamine agonist in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-31802006000500012

Thioridazine and sexual dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-31802006000500012

Effects of thioridazine on serum testosterone

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-31802006000500012

Prolactin levels and adverse events in patients treated with risperidone

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-31802006000500012

Prolactin Responses to Neuroleptics in Normal and Schizophrenic Subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-31802006000500012

Human prolactin responses to neuroleptic drugs correlate with antischizophrenic potency

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-31802006000500012

Mechanisms of action of atypical antipsychotic drugs: a critical analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-31802006000500012

Frequency of sexual dysfunction and other reproductive side-effects in patients with schizophrenia treated with risperidone, olanzapine, quetiapine, or haloperidol: the results of the EIRE study

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-31802006000500012

A randomized open-label study of the impact of quetiapine versus risperidone on sexual functioning

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-31802006000500012

Prolactogenic effects of risperidone in male patients--a preliminary study

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-31802006000500012

Clozapine versus typical antipsychotics. A retro- and prospective study of extrapyramidal side effects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-31802006000500012

What are the effects of antipsychotics on sexual dysfunctions and endocrine functioning?

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-31802006000500012

Reversal by bethanechol of sexual dysfunction caused by anticholinergic antidepressants

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-31802006000500012

Effects of psychotropic drugs on human erection and ejaculation

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS1516-31802006000500012

WITHDRAWN: Risperidone versus other atypical antipsychotic medication for schizophrenia.

21 January 2018

1 reference

12 January 2024

https://opencitations.net/index/api/v1/citations/10.1002/14651858.CD002306.PUB2

Identifiers

DOI

10.1590/S1516-31802006000500012

1 reference

24 July 2017

1 reference